Anika Therapeutics, Inc. (ANIK)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 4
Do Nothing: avgDollarVolume20 is $1.60M, below the strategy's $5.0M liquidity floor.
Company overview
Anika Therapeutics, Inc. specializes in joint preservation and orthopedic care, focusing on osteoarthritis pain management, regenerative solutions, and bone-preserving technologies. The company utilizes proprietary hyaluronic acid technology for its products, including treatments like Monovisc and Orthovisc. Established in 1983, Anika is headquartered in Bedford, Massachusetts.
Fundamental
fairThe company shows balance sheet strength but faces weak profitability and cash flow challenges.
FundamentalScore 3/5 (Mixed): balance sheet strength and improving 2026 quarterly results contrast with weak trailing profitability and limited free cash flow. Revenue compounded down about -6.53% annually from 2021–2025, though the latest quarter showed strong YoY growth and margin recovery. Valuation is reasonable on EV/Sales (~2.00) but looks expensive on EV/EBITDA (~88.97) with a low free-cash-flow yield (~0.22%). SEC filings highlight material customer concentration (J&J MedTech ~50% of 2025 revenue) and regulatory-approval timing risks.
Sentiment
goodRecent earnings and guidance updates have generated a favorable sentiment, despite limited retail engagement.
The dominant near-term driver is the Q2 2026 earnings beat and guidance raise (announced 2026-07-29), which is still within the post-earnings digestion window; last ~14d media tone is bullish, but the 30–90d baseline sample is sparse so the sentiment delta is indeterminate. No regulator-confirmed legal issues surfaced; Red-Flag Screen clean.
Technical
goodThe stock is in a strong uptrend above key averages, but liquidity is a concern.
Price 20.16 is above SMA20/50/200 (16.61/15.56/12.74), EMA9/21 (18.53/17.15), and the latest daily VWAP 19.98, while MACD 1.2 is above the 0.72 signal and ADX 54.95 confirms a strong uptrend. The caution flags are RSI 71.38 and Williams %R -14.68, which show the move is extended after the late-July range expansion and now digesting below 21.12 resistance.
You’re looking at 2026-08-06 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.